export default function Tb500OverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        TB-500 is the most popular injury recovery peptide in the community after BPC-157 &mdash; used by athletes with nagging tendon injuries, joint pain, and chronic inflammation that hasn&rsquo;t responded to rest and conventional treatment. Its evidence base is borrowed from research on a related compound, direct human trials don&rsquo;t exist, and the &ldquo;what&rsquo;s actually in the vial&rdquo; question is a real sourcing challenge.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; An injury that won&rsquo;t heal</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve had a nagging tendon issue for months that physical therapy hasn&rsquo;t fixed &mdash; people on forums say TB-500 helped them. Is there something real here?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Community reports consistently describe accelerated recovery from soft tissue injuries</strong><br />Across athletic forums, TB-500 has one of the strongest community consensus profiles in the peptide space: people with chronic tendinopathies, partial tears, and joint inflammation report meaningful improvement in timelines that conventional treatment hadn&rsquo;t achieved. This isn&rsquo;t random noise &mdash; the pattern is consistent enough to take seriously even without clinical trial data.</li>
          <li><strong>A plausible biological mechanism for what it&rsquo;s claimed to do</strong><br />TB-500 is derived from a protein that regulates actin &mdash; a structural protein critical to cell movement and tissue repair. The related compound it&rsquo;s based on has been studied for decades in wound healing, cardiac repair, and anti-inflammatory contexts in animal models. The mechanism isn&rsquo;t invented; it&rsquo;s just not proven in human clinical trials specifically for TB-500 as sold.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">You are injecting a research peptide from an unregulated supplier with no human clinical trial data. The evidence is inferred from 30+ years of animal studies on a related compound &mdash; useful context, but not a direct safety or efficacy guarantee. People with cancer history or active cancer treatment should not use TB-500 without oncology clearance, because the tissue growth signals it promotes are also the kind that cancer cells exploit. Net: a reasonable experiment for healthy adults with chronic soft tissue injuries who understand the evidence limitations; an absolute stop if you have cancer history.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; Chronic injury or high training load</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I train hard and I&rsquo;m always managing some level of tendon soreness or minor joint damage &mdash; does TB-500 actually help, and does stacking it with BPC-157 make sense?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The most community-supported option for tendon and soft tissue recovery</strong><br />Among performance athletes &mdash; strength sports, combat sports, endurance athletes &mdash; TB-500 is the peptide discussed most specifically for tendon injuries, partial tears, and chronic joint inflammation. The community consensus is the most specific and consistent of any recovery peptide: it&rsquo;s not general wellness claims, it&rsquo;s specific injury contexts with reported outcomes that track the mechanism.</li>
          <li><strong>Complementary stack logic with BPC-157</strong><br />BPC-157 and TB-500 are almost always discussed together in athletic recovery contexts, and for good reason: they work on different parts of the repair process. BPC-157 targets the healing environment (blood vessel growth, growth factor signaling, GI protection). TB-500 targets actin regulation and the inflammatory component of tissue damage. They&rsquo;re not redundant &mdash; they hit different mechanisms that both matter for tissue repair.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Attribution is the genuine challenge for athletes: TB-500 is almost always used alongside rehabilitation work, training load reduction, and often other compounds. Isolating what TB-500 specifically contributed is nearly impossible in practice. Set a clear, specific hypothesis with a defined evaluation window before starting &mdash; soft tissue comfort, range of motion in a specific joint, pain-free load at a specific exercise. Without a specific target and timeline, you won&rsquo;t know what worked. Net: one of the better-supported options for chronic tendon and soft tissue issues; stack with BPC-157 is coherent; verify your source has a third-party certificate of analysis.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; Tissue repair biology and actin regulation</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand what TB-500 actually is mechanistically &mdash; is the actin-sequestering fragment the active component, and how does that differ from full thymosin beta-4? And what does the cancer interaction risk actually mean at the mechanistic level?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The actin-binding fragment hypothesis is mechanistically coherent</strong><br />Full thymosin beta-4 (Tβ4) is a 43-amino acid protein that regulates actin polymerization &mdash; critical for cell motility and tissue repair. TB-500 as sold is typically the fragment Tβ4(17-23), the actin-sequestering region that&rsquo;s proposed to be the biologically active part. The reasoning is that this fragment delivers the core actin-regulatory function at a smaller molecular weight. Whether this fragment replicates the full protein&rsquo;s effects or only a subset of them is genuinely unresolved &mdash; but the mechanistic hypothesis is grounded in real Tβ4 biology, not invented.</li>
          <li><strong>Anti-inflammatory and angiogenic signals alongside actin regulation</strong><br />Full Tβ4&rsquo;s biological profile includes more than actin regulation: it promotes angiogenesis (new blood vessel formation, relevant to healing tissue), reduces inflammatory signaling (relevant to chronic tendinopathy where inflammation is both protective and limiting), and has been studied in cardiac repair contexts. Whether the TB-500 fragment shares these broader effects or only the actin-sequestering function is a real open question.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The cancer caution is not theoretical: angiogenic signaling (new blood vessel formation to feed healing tissue) is also how tumors establish their blood supply. Full Tβ4 has shown pro-angiogenic effects that are beneficial for tissue repair but potentially problematic in a context where tumor cells are present. The angiogenesis risk in the fragment form is less characterized, but the caution stands until better data exists. Additionally, what you receive as &ldquo;TB-500&rdquo; from research vendors varies: some products are full Tβ4, some are the fragment, some are mislabeled entirely. Third-party testing is not optional if you want to know what you&rsquo;re actually injecting. Net: a well-grounded research hypothesis with real mechanism; verify sourcing rigorously and do not use with cancer history.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What TB-500 is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Validated in human clinical trials &mdash; evidence is inferred from animal thymosin beta-4 research</li>
              <li>Safe with cancer history or active treatment &mdash; hard stop; angiogenic and tissue-growth signals require oncology clearance</li>
              <li>Guaranteed to be what it says on the label &mdash; product identity varies significantly between vendors</li>
              <li>A substitute for rehabilitation &mdash; it&rsquo;s a potential accelerant, not a replacement for appropriate treatment</li>
              <li>Something with characterized long-term safety data &mdash; no safety map exists for continuous human use</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>Strongest community consensus of any recovery peptide for tendon and soft tissue injuries</li>
              <li>Mechanistically coherent: actin regulation, anti-inflammatory signals, and angiogenic support for tissue repair</li>
              <li>30+ years of thymosin beta-4 preclinical research provides genuine biological context</li>
              <li>Complementary (not redundant) with BPC-157 for stacked recovery protocols</li>
              <li>Specific community use cases (chronic tendinopathy, partial tears) with the most consistent reports of any research peptide</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
